BioCentury
ARTICLE | Clinical News

PrEP-001: Phase IIa data

September 19, 2016 7:00 AM UTC

A double-blind Phase IIa trial in 63 healthy volunteers challenged with influenza virus showed that nasal PrEP-001 reduced the number of flu symptoms vs. placebo. hVIVO is developing PrEP-001 in colla...